Clinical Trials

1,000 enrolled

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01563874 2026-03-11

Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins

Completed

130 enrolled

Lymphoma

NCT05237986 2026-03-09

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

60 enrolled

Leukemia, Lymphoma

NCT06856226 2026-03-09

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

88 enrolled

Leukemia, Lymphoma, Hematologic Neoplasms

NCT00039676 2026-03-06

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Active not recruiting

1,836 enrolled

GenitourinaryLymphoidPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00352924 2026-03-06

Agriculture Health Study

Active not recruiting

89,655 enrolled

Lymphoma, Multiple Myeloma, Neoplasms, Prostatic Neoplasms

NCT01441089 2026-03-06

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

BreastGenitourinaryGynecologicLymphoidThoracic

1,100 enrolled

Breast Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT03258567 2026-03-06

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2 Recruiting

40 enrolled

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT03226704 2026-03-05

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

Enrolling by invitation

120 enrolled

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00006518 2026-02-25

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

1,029 enrolled

LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Lymphoma, Neoplasms, Sarcoma, Kaposi, Virus Diseases, Lymphoma, Primary Effusion

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00339963 2026-02-20

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma

Completed

1,340 enrolled

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00900198 2026-02-20

Collection of Tissue Samples for Cancer Research

LymphoidMyeloidPlasma cell

5,000 enrolled

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms

NCT05170399 2026-02-05

Vaccine Responses in Patients With B Cell Malignancies

Phase 4 Recruiting

500 enrolled

Phase 1/2 Active not recruiting

Lymphoma

NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

31 enrolled 14 charts

LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

NCT04320888 2025-12-04

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

1 enrolled 3 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04439110 2025-11-21

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

38 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439149 2025-11-21

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

24 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439188 2025-11-19

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

35 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439266 2025-11-19

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

5 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439279 2025-11-19

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439344 2025-11-19

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

53 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439175 2025-11-18

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

70 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06390852 2025-11-04

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

35 enrolled

Lymphoma, Multiple Myeloma

NCT06390865 2025-11-04

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

49 enrolled

Lymphoma, Multiple Myeloma

NCT04439227 2025-10-31

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06357975 2025-10-31

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

50 enrolled

Lymphoma, Multiple Myeloma

NCT06357988 2025-10-20

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

35 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma

NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Phase 1/2 Completed

34 enrolled 18 charts

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT04439253 2025-09-18

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT01051635 2025-07-17

A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

Phase 1 Completed

55 enrolled

Lymphoma, Neoplasms

NCT03269578 2025-07-01

Sample Collection and Tracking for the Developmental Therapeutics Clinic

3,000 enrolled

Lymphoma, Neoplasms

NCT00001379 2025-06-19

Treatment and Natural History Study of Lymphomatoid Granulomatosis

Phase 2 Completed

94 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 1 Completed

54 enrolled 24 charts

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02631746 2025-03-14

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Phase 2 Completed

3 enrolled 8 charts

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Phase 2 Completed

19 enrolled 18 charts